U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H18I6N2O9.C7H17NO5
Molecular Weight 1411.0267
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IOTROXATE MEGLUMINE

SMILES

CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)C1=C(I)C=C(I)C(NC(=O)COCCOCCOCC(=O)NC2=C(I)C(C(O)=O)=C(I)C=C2I)=C1I

InChI

InChIKey=WLQIGBUDSUVJCO-WZTVWXICSA-N
InChI=1S/C22H18I6N2O9.C7H17NO5/c23-9-5-11(25)19(17(27)15(9)21(33)34)29-13(31)7-38-3-1-37-2-4-39-8-14(32)30-20-12(26)6-10(24)16(18(20)28)22(35)36;1-8-2-4(10)6(12)7(13)5(11)3-9/h5-6H,1-4,7-8H2,(H,29,31)(H,30,32)(H,33,34)(H,35,36);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

HIDE SMILES / InChI
Iotroxic acid (INN), also known as meglumine iotroxate (BAN) (Biliscopin) for infusion is indicated for radiological examination of the hepatic and biliary ducts and gallbladder when examination by oral technique is unsuccessful or inappropriate. Following intravenous administration Biliscopin is rapidly excreted, mainly by the liver into the bile. Visualisation of the hepatic and common bile ducts and the gallbladder can, therefore, be achieved. Visualisation of the biliary ducts is usually possible 30-60 minutes after completion of administration. In vitro meglumine iotroxate binds to plasma proteins to the extent of 60-90% depending on concentration. In animals it crosses the placental barrier. This agent is the single intravenous cholangiographic agent, which is currently available in Australia.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Biliscopin

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
[Pharmacology of iotroxic acid, a new intravenous cholangiographic agent. II. Experimental animal study of side effects].
1978
Patents

Sample Use Guides

One bottle (100 mL) for infusion (1 mL=20 drops)
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Name Type Language
IOTROXATE MEGLUMINE
JAN   WHO-DD  
Common Name English
BENZOIC ACID, 3,3'-(OXYBIS(2,1-ETHANEDIYLOXY(1-OXO-2,1-ETHANEDIYL)IMINO))BIS(2,4,6-TRIIODO-, COMPD. WITH 1-DEOXY-1-(METHYLAMINO)-D-GLUCITOL (1:2)
Common Name English
IOTROXAMIDE
Common Name English
Iotroxate meglumine [WHO-DD]
Common Name English
D-GLUCITOL, 1-DEOXY-1-(METHYLAMINO)-, 3,3'-(OXYBIS(2,1-ETHANEDIYLOXY(1-OXO-2,1-ETHANEDIYL)IMINO))BIS(2,4,6-TRIIODOBENZOATE) (2:1)
Common Name English
IOTROXATE MEGLUMINE [JAN]
Common Name English
MEGLUMINE IOTROXATE
Common Name English
MEGLUMINE IOTROXINATE
Common Name English
Code System Code Type Description
ChEMBL
CHEMBL2110616
Created by admin on Fri Dec 15 18:05:35 GMT 2023 , Edited by admin on Fri Dec 15 18:05:35 GMT 2023
PRIMARY
MESH
C012386
Created by admin on Fri Dec 15 18:05:35 GMT 2023 , Edited by admin on Fri Dec 15 18:05:35 GMT 2023
PRIMARY
DRUG BANK
DBSALT002658
Created by admin on Fri Dec 15 18:05:35 GMT 2023 , Edited by admin on Fri Dec 15 18:05:35 GMT 2023
PRIMARY
CAS
68890-05-1
Created by admin on Fri Dec 15 18:05:35 GMT 2023 , Edited by admin on Fri Dec 15 18:05:35 GMT 2023
PRIMARY
PUBCHEM
119297
Created by admin on Fri Dec 15 18:05:35 GMT 2023 , Edited by admin on Fri Dec 15 18:05:35 GMT 2023
PRIMARY
FDA UNII
389136RRO0
Created by admin on Fri Dec 15 18:05:35 GMT 2023 , Edited by admin on Fri Dec 15 18:05:35 GMT 2023
PRIMARY
EVMPD
SUB02755MIG
Created by admin on Fri Dec 15 18:05:35 GMT 2023 , Edited by admin on Fri Dec 15 18:05:35 GMT 2023
PRIMARY
RXCUI
52527
Created by admin on Fri Dec 15 18:05:35 GMT 2023 , Edited by admin on Fri Dec 15 18:05:35 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID80218969
Created by admin on Fri Dec 15 18:05:35 GMT 2023 , Edited by admin on Fri Dec 15 18:05:35 GMT 2023
PRIMARY
SMS_ID
100000092771
Created by admin on Fri Dec 15 18:05:35 GMT 2023 , Edited by admin on Fri Dec 15 18:05:35 GMT 2023
PRIMARY